Pulmonary arterial hypertension is a severe and progressive disease, a hallmark of which is pulmonary vascular remodeling. Nicotinamide phosphoribosyltransferase (NAMPT) is a cytozyme that regulates intracellular nicotinamide adenine dinucleotide levels and cellular redox state, regulates histone deacetylases, promotes cell proliferation, and inhibits apoptosis. We hypothesized that NAMPT promotes pulmonary vascular remodeling and that inhibition of NAMPT could attenuate pulmonary hypertension.
P
ulmonary arterial hypertension (PAH) is a progressive disease caused by functional and structural changes in the pulmonary vasculature that lead to increased pulmonary vascular resistance and eventually right ventricular (RV) failure and death. PAH is characterized by vasoconstriction, in situ thrombosis, vascular inflammation, and pulmonary artery smooth muscle cell (PASMC) and pulmonary artery endothelial cell (PAEC) proliferation and apoptosis resistance. 1 PAEC dysfunction and injury are believed to play a critical role in the pathogenesis of the disease and can trigger PASMC proliferation and migration through activation of growth factors or disruption of cell survival mediators. 2, 3 Although important progress has been made in recent years, the precise cellular and molecular basis of pulmonary vascular remodeling in PAH continues to evolve, and the discovery of therapeutic targets that attenuate vascular remodeling is ongoing.
Nicotinamide phosphoribosyltransferase (NAMPT), also called visfatin and pre-B cell colony-enhancing factor, was first characterized as a cytokine acting on early B-lineage precursor cells and is a pleiotropic protein with extracellular proinflammatory cytokine-like activity and intracellular enzymatic activity as a phosphoribosyltransferase. [4] [5] [6] [7] [8] [9] [10] It has been demonstrated as the rate-limiting component of the mammalian nicotinamide adenine dinucleotide (NAD) biosynthesis pathway from nicotinamide. 11 NAMPT activity has been linked to several processes involving cellular adaptation to stress responses. These include resistance to senescence, apoptosis, and increase in cell proliferation and regulation of cellular redox state. [6] [7] [8] 12, 13 At the pathological level, NAMPT promotes inflammatory responses by increasing inflammatory cell survival and increasing proinflammatory cytokine production. 8, [14] [15] [16] NAMPT is also upregulated in many types of malignancies in which it promotes cell survival, proliferation, and resistance to chemotherapeutic agents. 7, [17] [18] [19] [20] [21] In vascular cells, NAMPT promotes endothelial cell survival and angiogenic activity, as well as smooth muscle cell survival. 10, 13, [22] [23] [24] We therefore hypothesized that NAMPT may play an important role in PAH pathobiology by promoting pulmonary vascular remodeling during pulmonary hypertension (PH) development and that inhibition of NAMPT could attenuate experimental PH.
METHODS Human Lung Tissues, Human PAECs, and Human PASMCs
Approval for the collection of plasma and the use of human lung tissues and cells was granted by Institutional Review Boards of participating centers. Plasma samples were obtained from 103 patients with PAH defined by the 2013 Nice classification 25 and 53 control subjects, including patients with hypothyroidism, osteoporosis, nephrolithiasis, diabetes mellitus, osteoarthritis, and hypertension. Deidentified human explanted peripheral lung tissues and PAECs used in this study were from 4 control subjects (2 unsuitable organ donors and 2 patients with chronic obstructive pulmonary disease without PH) and patients with idiopathic PAH (4 patients diagnosed on the basis of National Institutes of Health PAH Registry criteria) obtained at the Cleveland Clinic Foundation. PAECs were isolated as previously described. 26 In addition, primary human PASMC (hPASMC) and human PAEC (hPAEC) cell lines from Lonza (CC-2581 and CC-2530) were used for cell transfection and proliferation assays. Cells were cultured at 37°C in their complete medium with 10% FBS and studied at passages 5 through 8.
Reagents, Pharmacological Inhibitors, and Antibodies
Information on reagents, pharmacological inhibitors, and antibodies is provided in the online-only Data Supplement.
Western Blotting
Solubilized protein lysates isolated from lung tissues and cells were used to detect NAMPT, stromal interaction molecule 2 (STIM2), Orai2, and β-actin. Cells were lysed in a modified radioimmunoprecipitation assay lysis buffer with a protease and phosphatase inhibitor cocktail (Sigma Aldrich, St. Louis, MO), and protein quantification and Western blot analysis were performed according to standard procedures.
RNA Isolation and Real-Time Polymerase Chain Reaction
Total RNA from lung tissues or cells was isolated with the RNeasy Plus Mini Kit (catalog No. 74134, Qiagen). Purified RNA (2 μg) was reversely transcribed to single-stranded cDNA with the Taqman RNA reverse transcription kit (catalog No. N8080234, Applied Biosystems, Inc). Real-time polymerase chain reaction was performed on an Applied Biosystems, Inc 7900HT machine. Specific Taqman quantitative real-time polymerase chain reaction assays were ordered from Applied Biosystems, Inc (specific assay identifications available on request). The relative mRNA expression levels were normalized to the expression of a housekeeping gene, glucose-6-phosphate
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dehydrogenase (G6PDH), and determined by calculating the ΔΔCt value, as detailed in the manufacturer's guidelines.
Mouse PASMC Isolation
A mixture of 5 mL medium 199 growth medium containing 5 g/L low-melting-point agarose type VII (Sigma), 5 g/L iron beads (diameter <10 μm; Sigma), and antibiotics (penicillin and streptomycin) was slowly injected over a period of 60 seconds through the RV, thereby perfusing the pulmonary artery. Medium 199 growth medium (1 mL) containing 5 g/L agarose type VII was injected into airways through the trachea. The lungs were plunged in cold PBS to cause the agarose to gel. Because of the rapidly solidifying nature of the agarose and the size of the iron particles, the likelihood of traversing the capillary space is minimized. All the lobes were then isolated and finely minced in a Petri dish. The tissue was further disrupted by passing through a 16-gauge followed by an 18-gauge needle ≈5 times. The suspension was then mixed in medium 199 growth medium containing 80 U/mL type IV collagenase (Sigma) and incubated at 37°C for 90 minutes. With the use of a magnetic column (Invitrogen), the arteries or arterial tissues containing the iron beads were collected. The supernatant was aspirated, and the arteries were washed and suspended in 5 mL medium 199 containing 20% FBS. Aliquots of the suspension were transferred to T25 culture flasks. Cells from the hypoxic group were incubated at 3% O 2 , whereas cells from the normoxic control were cultured in air. Smooth muscle cell purity was determined by immunostaining with smooth muscle-specific α-actin antibody.
Cell Proliferation Assays
Cell proliferation was determined with either a BrdU incorporation assay or cell counting. BrdU assays (QIA58, Calbiochem, San Diego, CA) were performed in a 96-well format according to manufacturer's instructions with starting cell densities of 4000 cells per well. For cell counting, cells were trypsinized and resuspended after experimental procedures; densities were counted with a TC10 automated cell counter (Bio-Rad). FBS or platelet-derived growth factor were used as positive controls.
Overexpressing NAMPT in hPASMCs and hPAECs
A human wild-type NAMPT expression sequence was cloned downstream of the ubiquitin promoter in a third-generation lentiviral plasmid. Separately, a control plasmid was generated by cloning a green fluorescent protein expression sequence in the same position. 
Animal Models of PH and Hemodynamic Measurements
All experiments were approved by the Ethics and Animal Care Committee of the University of Illinois at Chicago. Three rodent models of PH were used in this study. They included a mouse model of hypoxia-induced PH, a rat model of monocrotalineinduced PH, and a rat model of Sugen hypoxia-induced severe PH. Nampt −/− mice exhibit embryonic lethality; thus, Nampt +/− mice were used in this study. Male mice (8-week-old Nampt +/− mice on a C57BL/6 background and their wild-type siblings) were exposed to hypoxia (10% O 2 ) in a ventilated chamber for 4 weeks. Male Sprague-Dawley rats (190-200 g) were used for the monocrotaline-and Sugen hypoxia-induced PH studies.
In the monocrotaline-induced PH model, monocrotaline was dissolved in 0.5N HCl to 200 mg/mL, neutralized to pH 7.4 with 0.5N NaOH, and then diluted with sterile water to 60 mg/ mL. One dose of monocrotaline (60 mg/kg body weight) was injected subcutaneously into rats. Control rats were injected with the equivalent volume of dissolvent solution according to their weights. Food and water were provided ad libitum, and the rats are checked once per day. For the prevention experiment, FK866 (2.5 mg/kg every 48 hours) was started on day 2 after the monocrotaline injection and continued for 2 weeks; for the therapeutic experiment, FK866 (2.5 mg/kg every 48 hours) was started day 14 after the monocrotaline injection and continued for 2 weeks. Our historical data show that rats on day 14 after monocrotaline injection develop PH as demonstrated by significantly increased RV systolic pressure (RVSP) and RV hypertrophy (RVH; Figure I in the online-only Data Supplement). Each group included 6 to 8 rats. In the Sugen hypoxia PH model, 1 dose of Sugen (20 mg/kg) was given subcutaneously at the first day of hypoxia exposure (10% O 2 ). After 3 weeks of constant hypoxia exposure, the rats were returned to room air. FK866 (2.5 mg/kg every 48 hours) was then started 2 weeks after reoxygenation and continued for 3 weeks. Each group included 10 to 12 rats. Hemodynamic data after 2-week reoxygenation indicate that rats develop significant PH at this time point ( Figure II in the online-only Data Supplement). RVSP was determined by right-sided heart catheterization with a Millar pressure transducer catheter. A weight ratio of the RV divided by the sum of left ventricle and septum was measured to determine the extent of RVH. The RV contractility index was calculated as (dP/dt) max /instantaneous RV pressure max , as previously described. 27 Pulmonary artery remodeling was assessed with Aperio ImageScope software (version 11) after lungs were stained with hematoxylin and eosin. A minimum of 10 microscopic fields were examined for each slide. Approximately 20 muscular arteries with diameters of 50 to 100 or <50 μm per lung section were outlined and measured. Vessel remodeling was calculated as [(external vessel area−internal vessel area)/ external vessel area], as previously described. 28 Occlusive pulmonary arteries were counted from hematoxylin and eosinstained lung slides from each group.
Statistical Analysis
Statistical analysis of experimental data was performed with GraphPad Prism 5.1 (GraphPad Software, Inc, La Jolla, CA). Results are expressed as mean±SEM except where noted from at least 3 experiments. The Student t test and ANOVA were used to compare 2 and 3 groups, respectively, except for the comparison of NAMPT plasma levels between control and PAH subjects, for which a Mann-Whitney test was used. A value of P<0.05 was considered statistically significant.
RESULTS

NAMPT Is Upregulated in Patients With PAH and in Experimental Rodent PH Models
Plasma NAMPT levels were significantly elevated in patients with PAH (n=103; median, 3197; interquartile range, 1493-7280) compared with controls (n=53; median, 1686; interquartile range, 990-2608; P<0.001 by Mann-Whitney test; Figure 1A and Table I in A similar pattern was found in different rodent models of PH, including a mouse model of hypoxia-mediated PH (10% hypoxia for 4 weeks; Figure 2A ), a rat model of monocrotaline-induced PH (2 weeks after administration of monocrotaline [60 mg/kg body weight SC]; Figure 2B) , and a rat model of the vascular endothelial growth factor receptor blocker Sugen plus hypoxia mediated PH (Sugen [20 mg/kg body weight SC] followed by 10% hypoxia for 3 weeks and normoxia for 3 weeks; Figure 2C ). In addi- Figure 1 . Plasma nicotinamide phosphoribosyltransferase (NAMPT) levels and mRNA and protein levels of NAMPT in the lungs and pulmonary artery endothelial cells (PAECs) are upregulated in patients with pulmonary arterial hypertension (PAH).
A, Plasma NAMPT levels are higher in patients with PAH (n=103) compared with control subjects without PAH (n=53). B, NAMPT mRNA levels are upregulated in the lungs of the patients with PAH (n=4) compared with control subjects without PAH (n=4). C and D, Representative Western blotting images and β-actin-normalized quantification of protein demonstrate that NAMPT expression is significantly increased in lungs from patients with PAH compared with control subjects without PAH. E and F, Representative Western blotting images and β-actin-normalized quantification of protein demonstrate that NAMPT protein levels were upregulated in PAECs isolated from patients with PAH (n=3) compared with control subjects without PAH (n=3). Results are expressed as mean±SEM. *P<0.05, ***P<0.001 vs control. tion, the NAMPT expression profiles in lung tissues from these different rodent models of PH were examined with immunofluorescence staining. As shown in Figures V and VI in the online-only Data Supplement, NAMPT expression in experimental PH appears to increase in the pulmonary vasculature mainly in PAECs and the adventitia, but not in the media, as well as in airway and alveolar epithelial cells. Alveolar macrophages also express NAMPT, especially in the rat model of PH mediated by monocrotaline, as demonstrated by CD68 immunostaining (data not shown).
In aggregate, these results suggest that NAMPT may play a role in the development of PH.
NAMPT Heterozygous (Nampt
To examine the effect of NAMPT on the development of PH, Nampt +/− mice and their wild-type siblings on a C57BL6 background were exposed to 10% hypoxia for 4 weeks. Compared with wild-type siblings, Nampt +/− mice exhibited significantly lower baseline levels of NAMPT and NAD in lung tissue homogenates ( Figure VII in the online-only Data Supplement). After a 4-week hypoxia exposure, Nampt +/− mice displayed significantly lower RVSP ( Figure 3A) , decreased RVH (assessed by ratio of the RV to the sum of left ventricle and septum; Figure 3B ), and less severe pulmonary vascular remodeling in response to hypoxia compared with control mice (Figure 3C-3E) . Furthermore, PASMCs isolated from Nampt +/− mice were less proliferative compared with wild-type mice as demonstrated by BrdU incorporation and cell counting (Figure 3F and 3G) . Similarly, silencing NAMPT via siRNA attenuated complete medium, hypoxia, or platelet-derived growth factor-mediated hPASMC proliferation ( Figure VIII in the online-only Data Supplement.
NAMPT Activity Promotes PASMC Proliferation
In addition to increased expression, PAECs isolated from patients with PAH secreted more NAMPT in culture media than control cells ( Figure 4A ). Furthermore, conditioned media from PAECs isolated from patients with PAH significantly promoted hPASMC proliferation. This effect was significantly attenuated by the NAMPT enzymatic activity inhibitor FK866 21 ( Figure 4B ). Lentivirus-mediated NAMPT overexpression promoted both hPAEC and hPASMC proliferation ( Figure 4C-4I) . Compared with control cells, hPAECs overexpressing NAMPT secreted more NAMPT, and conditioned media from these cells stimulated more hPASMC proliferation ( Figure 4J ). These effects were attenuated by FK866 ( Figure 4F, 4I, and 4J) . Last, recombinant NAMPT protein (rNAMPT) promoted hPASMC proliferation in a dose-dependent manner (an effect that was attenuated by FK866; Figure 4K ) and enhanced hPASMC migration (an effect that was attenuated by FK866; Figure IX in the online-only Data Supplement). Taken together, these data suggest that NAMPT promotes hPASMC proliferation and migration in an autocrine and paracrine manner.
Inhibition of NAMPT Activity Promotes PASMC Apoptosis
Because NAMPT promotes resistance to apoptosis [6] [7] [8] and resistance to apoptosis is a major contributor to A, Representative Western blotting images and β-actin-normalized quantification of protein demonstrate that NAMPT expression is significantly increased in mouse lungs after a 4-week 10% hypoxia exposure. B, Representative Western blotting images and β-actin-normalized quantification of protein demonstrate that NAMPT expression is significantly increased in the lungs from a rat model of PH mediated by monocrotaline (MCT). C, Representative Western blotting images and β-actin-normalized quantification of protein demonstrate that NAMPT expression is significantly increased in the lungs from Sugen hypoxia-mediated PH in rats. **P<0.01 vs controls.
the pathobiology of PAH, we tested whether inhibition of NAMPT activity would promote PASMC apoptosis. As shown in Figure X in the online-only Data Supplement, treatment with FK866 induced hPASMC apoptosis. Furthermore, treatment with rNAMPT protected PASMCs against H 2 O 2 -induced apoptosis, an effect that was attenuated by concomitant FK866 treatment.
NAMPT Enhances SOCE in PASMCs
NAMPT activity promotes inflammatory responses, including the expression of inflammatory cytokines. For instance, NAMPT-derived NAD promotes tumor necrosis factor-α (TNF-α) synthesis by activated immune cells. 29 Because inflammatory pathways, particularly the cytokine TNF-α, have been shown to promote SOCE, 30, 31 we hypothesized that NAMPT-induced PASMC proliferation would be mediated by enhancement of SOCE. To test this hypothesis, we treated PASMCs with rNAMPT (20 µg/mL) for 48 hours. [Ca 2+ ] cyt was measured in PASMCs loaded with fura-2 acetoxymethyl ester (4 μmol/L) with a fluorescence microscope, and cyclopiazonic acid was used to induce SOCE. After 48 hours, rNAMPT treatment significantly enhanced cyclopiazonic acid-mediated SOCE in PASMCs ( Figure 5A ).
ORAI calcium release-activated calcium modulator 2 (Orai2) and STIM2 are upregulated in PASMCs from patients with PAH and contribute to enhanced SOCE and to the transition of these cells from a contractile to proliferative phenotype. 32 Given these findings, we tested whether NAMPT activity would enhance SOCE via upregulation of Orai2 and STIM2. NAMPT treatment increased the expression of both Orai2 and STIM2 (Figure 5B-5E proliferation ( Figure 5F ). These data suggest that SOCE is required for the proliferative effect of NAMPT in PASMCs.
Last, the effect of NAMPT on L-type calcium channel-mediated signaling was also examined. Blockage of L-type channels with verapamil did not affect rNAMPTmediated hPASMC proliferation ( Figure XI in the onlineonly Data Supplement).
Inhibition of NAMPT by FK866 Prevents and Attenuates Monocrotaline-Induced PH in Rats
To examine the potential therapeutic role of NAMPT inhibition in PH, we evaluated the effect of FK866 in monocrotaline-induced PH model in rats. In PH prevention experiments, FK866 (2.5 mg/kg every 48 hours IP) or vehicle was given to rats (n=6-8 animals per group) A, PAECs isolated from patients with pulmonary arterial hypertension secrete more NAMPT compared with control subjects without PAH (n=3 per group). B, BrdU incorporation assays demonstrate that cell culture medium of PAECs isolated from patients with PAH stimulates more PASMC proliferation and that this effect can be attenuated by the specific NAMPT inhibitor FK866 (10 μmol/L; ANOVA, P<0.05, control vs PAH). Overexpressing NAMPT in human PAECs (hPAECs) increases NAMPT expression and secretion (C-E). NAMPT overexpression promotes cell proliferation, and its proliferative effect is attenuated by FK866 (10 μmol/L; F; ANOVA, P<0.05, vehicle vs NAMPT and NAMPT+FK-866). Overexpressing NAMPT in hPASMCs (G and H) promotes cell proliferation, and its proliferative effect is attenuated by FK866 (I; ANOVA, P<0.05, control vs NAMPT and NAMPT+FK-866). Cell culture medium of PAECs overexpressing NAMPT stimulates more PASMC proliferation, and this effect is attenuated by FK866 (10 μmol/L; J; ANOVA, P<0.05, vehicle vs NAMPT and NAMPT+FK-866). K, Recombinant NAMPT protein stimulates human PASMC proliferation in a dose-dependent manner, and this effect is attenuated by FK866 (10 μmol/L, ANOVA, P<0.05 for the different NAMPT doses and NAMPT+FK-866 comparison). Results are expressed as mean±SEM. *P<0.05, **P<0.01, ***P<0.001 vs pairwise comparison indicated by brackets. FBS or platelet-derived growth factor was used as a positive control for BrdU proliferation assays as stated in the specific figures. starting 1 day after subcutaneous injection of monocrotaline (60 mg/kg body weight), and in PH-reversal experiments, FK866 (2.5 mg/kg every 48 hours IP) or vehicle was given to rats (n=6-8 animals per group) starting 14 days after monocrotaline injection (60 mg/kg body weight). Compared with vehicle, treatment with FK866 prevented ( Figure 6 ) and also attenuated ( Figure 7 ) the development of PH. In both experiments, FK866 treatment significantly reduced the PH assessed by the RVSP and RVH, the RV contractility index, and the degree of pulmonary artery muscularization. Furthermore, FK866 treatment decreased PASMC proliferation, as demonstrated by PCNA and smooth muscle actin double immunostaining of lung tissues ( Figure XII in the online-only Data Supplement).
Inhibition of NAMPT by FK866 Attenuates Sugen Hypoxia-Mediated PH in Rats
The rat model of PH mediated by Sugen and hypoxia induces severe pulmonary vascular remodeling characterized by obliterative pulmonary vascular lesions with neointima formation in distal pulmonary arteries. We assessed NAMPT inhibition by FK866 (2.5 mg/kg every 48 for 3 weeks) after rats (n=8-12 per treatment group) were given Sugen (20 mg/kg SC once), exposed to chronic hypoxia for 3 weeks, and then kept in normoxia for another 2 weeks. Compared with controls, FK866 treatment attenuated the development of PH assessed by changes in RVSP, RVH, and RV contractility index, as well as the development of medial hypertrophy and neointima formation (Figure 8 ). FK866 treatment also decreased cell proliferation in obliterative lesions ( Figure  XIII in the online-only Data Supplement). Taken together with the results from the monocrotaline studies, these data suggest that NAMPT inhibition is a novel therapeutic target in PAH.
DISCUSSION
Here, we show that NAMPT is upregulated in the plasma, lungs, and PAECs isolated from patients with PAH and in different rodent models of PH. PAECs from patients with PAH are more proliferative and secrete more NAMPT, which promotes PASMC proliferation in a paracrine fashion via calcium signaling. We also show that NAMPT contributes to pulmonary vascular remodeling in vivo and that pharmacological inhibition of NAMPT activity attenuates experimental PH. NAMPT is a multifunctional protein with extracellular proinflammatory cytokine-like activity and intracellular enzymatic activity as a phosphoribosyltransferase, which regulates NAD levels. 4 Therefore, NAMPT regulates the activity of NAD-dependent enzymes such as sirtuins and poly(ADP-ribose) polymerases and functions as a master regulator of cellular metabolism, mitochondrial biogenesis, and adaptive and maladaptive responses to cellular stress. 10 There are several potential mechanisms for the upregulation of NAMPT in patients with idiopathic PAH and in experimental models of PH. As major mediators contributing to PAH pathobiology, hypoxia, upregulation of growth factors, and inflammatory pathways can also influence NAMPT expression. The NAMPT promoter has hypoxia-inducible factor-responsive elements that affect the transcriptional regulation of NAMPT. 33, 34 The NAMPT promoter also contains binding sites for nuclear factor-1, activating protein-1, and nuclear factor-κB, and TNF-α, interleukin-1β, and interleukin-6 increase NAMPT expression. 9 Epigenetic regulation of NAMPT expression via microRNAs has been demonstrated in PAECs, 35 colorectal cancer cell lines, 36 hepatocytes, 37 and TZM-bl HeLa cell lines. 38 It is possible that similar effects could occur in the context of PAH. Further studies in this area are warranted. NAMPT levels are also increased and correlate with disease severity in metabolic syndrome and diabetes mellitus, [39] [40] [41] as well as coronary artery disease. 42 This suggests that NAMPT should be studied as a prognostic biomarker in PAH.
Uncontrolled PASMC proliferation and resistance to apoptosis are major contributors to the pathobiology of PAH. Our results demonstrate that NAMPT promotes PASMC proliferation in a dose-dependent manner, suggesting that it plays a significant role in the pulmonary vascular remodeling associated with PAH. Ca 2+ signaling in PASMCs promotes vascular remodeling through its stimulatory effect on PASMC proliferation and migration. Previous studies have shown that PASMCs from patients with idiopathic PAH exhibit enhanced SOCE compared with control PASMCs and that SOCE contributes to PASMC proliferation. 32, [43] [44] [45] [46] [47] Specifically, STIM2 and Orai2 both contribute to SOCE and are upregulated in PASMCs from patients with idiopathic PAH and from animals with experimental PH compared with controls, ultimately contributing to the transition of these cells from a contractile to a proliferative phenotype. 32, 47 We show that NAMPT enhances SOCE in PASMCs by increasing the expression of STIM2 and Orai2 and that inhibition of NAMPT activity decreases the expression of these 2 proteins. In line with these observations, Ye and colleagues 48 have shown that NAMPT knockdown blunted thrombin-mediated increases in Ca 2+ entry in human PAECs. We speculate that NAMPT activity could enhance SOCE by upregulating inflammatory pathways as shown in human aortic smooth muscle cells. 49 Inflammatory cytokines such as TNF-α have been known to increase agonist-induced [Ca 2+ ] i response and contractility in airway smooth muscle cells 31, [50] [51] [52] and to increase SOCE in these cells. 30, 31, 53 Furthermore, lipopolysaccharide-induced activation of both the nuclear factor-κB and p38 mitogen-activated protein kinase signaling pathways induces STIM1 expression in PAECs. 54 It is interesting to note that by increasing NAD levels, NAMPT promotes TNF-α synthesis via regulation of SIRT6 activity. 29, 55 The extracellular cytokine-like activity of NAMPT could also potentially activate nuclear factor-κB signaling and further enhance SOCE. 56, 57 The paracrine effects of NAMPT have been demonstrated in other studies. Pillai and colleagues 58 showed that cardiac-specific overexpressing NAMPT transgenic mice spontaneously developed cardiac hypertrophy and that treatment of cardiomyocytes with rNAMPT induced cardiomyocyte hypertrophy. Yoon and colleagues 59 demonstrated that deacetylation of lysine 53 in intracellular NAMPT by SIRT1 predisposes the protein to secretion by adipocytes and increases secreted extracellular NAMPT activity. Adipose tissue-specific NAMPT knockout and knock-in mice showed reciprocal changes in circulating NAMPT levels that affected hypothalamic NAD + and SIRT1 signaling and physical activity. Last, administration of an NAMPT-neutralizing antibody suppressed NAMPT enzymatic activity by 90% for rNAMPT in vitro and by 40% for extracellular NAMPT in plasma and decreased hypothalamic NAD + production in vivo. It is clear that given its pleiotropic effects, NAMPT can exert other effects that promote pulmonary vascular remodeling beyond inducing PASMC proliferation in a paracrine manner. For instance, our results and the work of others suggest that NAMPT activity directly promotes endothelial and smooth muscle cell proliferation. 12, 13 Our data from Nampt +/− mice and from NAMPT loss-offunction studies in hPASMCs also suggest that normal NAMPT levels are required to promote cell proliferation in both physiological and pathological conditions. By regulating cellular NAD levels and the activity of NAD-dependent enzymes such as sirtuins and ADP-ribosyltransferases, NAMPT plays an important role in the regulation of programmed cell death pathways. In models of acute inflammation, NAMPT activity prevents the apoptosis of neutrophils. 60 NAMPT also protects cells from apoptosis by inhibiting the activity of p53. [61] [62] [63] SIRT3 has also been found to prevent loss of mitochondrial membrane potential and cell death in response to hypoxia and staurosporine treatment. 64 Current and future studies by our group are seeking to elucidate the molecular mechanisms associated with increased proliferation and cell survival of PAECs and PASMCs in the context of PAH. Last, T and B lymphocytes and macrophages are present in increased numbers in and around the pulmonary arteries of patients with PAH, and these cells could be another source of NAMPT within the PAH lung microenvironment. 65 Our results show that NAMPT inhibition with FK866 has therapeutic effects in preclinical models of PH by attenuating pulmonary vascular remodeling characterized by medial hypertrophy and neointima formation. FK866 specifically inhibits NAMPT activity likely by functioning as a substrate (NAM) mimetic that leads to a decrease is NAD synthesis. 21 NAMPT inhibitors have been shown to have therapeutic effects in preclinical studies by inhibiting cell proliferation and promoting apoptosis in cancer models, 21 inhibiting T-cell proliferation and survival in autoimmune encephalomyelitis, 55 inhibiting inflammatory cytokine production in collagen-induced arthritis, 66 and inducing neutrophil apoptosis in lipopolysaccharide-induced acute lung injury. 60 NAMPT inhibitors have also been studied in phase I to II human clinical trials in patients with cancer. [67] [68] [69] [70] In these studies, the main dose-limiting toxicities included hematologic abnormalities (thrombocytopenia, leukopenia, and anemia) and several gastrointestinal symptoms such as nausea, vomiting, anorexia, and abdominal pain. [67] [68] [69] [70] Our hemodynamic studies are limited by an indirect assessment of pulmonary artery pressures via measurement of RVSP and lack of a direct assessment of cardiac output or left ventricular function. Further animal and human studies are needed to completely characterize the effects of NAMPT inhibition on the pulmonary and systemic vasculatures and its effects on RV and left ventricular function. The results of our preclinical studies also highlight the relative limitations of the existing experimental PH models. NAMPT inhibition had a much more pronounced therapeutic effect in the monocrotaline than in the Sugen hypoxia PH model. This is consistent with the notion that the Sugen hypoxia PH model more closely mimics the severe pulmonary vascular remodeling and PH associated with human PAH, suggesting that this model is likely more suitable to test the translational potential of novel therapeutic strategies for the disease.
CONCLUSIONS
We have demonstrated that NAMPT promotes pulmonary vascular remodeling and contributes to PAH pathobiology. Most important, our results suggest that NAMPT is a novel potential therapeutic target for PAH that should be explored in future preclinical and clinical studies.
